Compare ESLT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | ILMN |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.6B | 37.0B |
| IPO Year | 2002 | 2000 |
| Metric | ESLT | ILMN |
|---|---|---|
| Price | $667.67 | $271.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $801.33 | $233.55 |
| AVG Volume (30 Days) | 62.2K | ★ 3.7M |
| Earning Date | 11-17-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.57% | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $4,343,000,000.00 |
| Revenue This Year | $14.70 | $6.48 |
| Revenue Next Year | $11.63 | $6.46 |
| P/E Ratio | ★ $71.88 | $124.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $453.00 | $90.10 |
| 52 Week High | $1,016.06 | $309.35 |
| Indicator | ESLT | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 59.30 |
| Support Level | $647.25 | $116.43 |
| Resistance Level | $735.17 | $309.35 |
| Average True Range (ATR) | 13.60 | 14.89 |
| MACD | -4.54 | -1.41 |
| Stochastic Oscillator | 12.25 | 35.77 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security and commercial flight capabilities. Its systems and solutions may be installed on new platforms or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company operates in five segments: Aerospace; C4I and Cyber; ISTAR and EW; Land; and ESA. It derives maximum revenue from Land Segment. Geographically, it operates in Israel; North America; Europe; Asia-Pacific; Latin America; and Others.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.